It’s a fairly common trait for most of us to seek antibiotics when we contract an infection or have a less than mild cough and cold. We therefore often take it for granted that there is an endless supply of such a product.
The news that the supply of antibiotics such as amoxicillin are running low in the US, highlights the fact that even the most common drugs, produced by the very largest pharmaceutical manufacturers, can still become a very scarce commodity in the current market
{
“The combination in rapid succession of the pandemic impact and consequent demand swings, manufacturing capacity constraints, scarcity of raw materials, and the current energy crisis means we face a uniquely difficult situation in the short term”
More posts by John Wadsworth
